Ebola Virus Triage Test Granted Emergency Use Authorization
|
By LabMedica International staff writers Posted on 14 Jun 2016 |
|
Image: The Idylla fully automated, real-time polymerase chain reaction (rt-PCR) based molecular diagnostics system (Photo courtesy of Biocartis).
The 2014 Ebola virus outbreak in West Africa was the largest outbreak since its discovery 40 years ago and with over 11,000 deaths reported and affecting multiple countries, that outbreak demonstrated a clear need for improved infectious disease surveillance and management.
Today, further preparation is needed, as specialists expect sporadic Ebola virus outbreaks to continue in the future. A molecular diagnostic test for the Ebola Zaire virus has received Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA, Silver Springs, MD, USA) and may be used to detect Ebola Zaire virus in patients with signs and symptoms of Ebola virus disease.
The Idylla Ebola Virus Triage Test (Biocartis, Mechelen, Belgium) is a real-time reverse transcription polymerase chain reaction (rRT–PCR) test intended for the qualitative detection of ribonucleic acid (RNA) from the Ebola Zaire virus that was detected in the West Africa outbreak in 2014, in Ethylenediaminetetraacetic acid (EDTA) venous whole blood from individuals with signs and symptoms of Ebola virus infection in conjunction with epidemiological risk factors. The test, which delivers results within 100 minutes on a single cartridge, runs on the Biocartis Idylla platform, a fully automated, sample-to-result, real-time RT-PCR system, which allows for rapid deployment in both developed and emerging market countries.
The Idylla Ebola Virus Triage Test sample manipulation is reduced to a single step, i.e. entering the blood sample into the Idylla cartridge, after which the cartridge becomes a hermetically closed container. This reduces the risk of exposure to the Ebola virus for healthcare workers. Furthermore, the Idylla Ebola Virus Triage Test requires only minimal training of healthcare professionals and can be transported and stored at ambient temperature conditions, which enables rapid global deployment during outbreaks. Due to the difficulty in obtaining clinical specimens positive for Ebola, the Idylla Ebola Virus Triage Test was evaluated with limited numbers of contrived specimens spiked with live Ebola Zaire virus RNA.
Rudi Pauwels, PhD, Founder and Chief Executive Officer at Biocartis, said, “The 2014 Ebola and more recently the Zika outbreak, demonstrates that in today’s global world we need rapid, highly accurate and easily deployable diagnostic systems. The Idylla Ebola Virus Triage Test is the first infectious disease outbreak test authorized by the FDA on our Idylla platform, which is perfectly suited for outbreak control through early and fast testing. The test allows healthcare professionals in the field to rapidly diagnose infection, implement control measures and as such, open doors to faster and better treatment decisions.”
Related Links:
US Food and Drug Administration
Biocartis
Today, further preparation is needed, as specialists expect sporadic Ebola virus outbreaks to continue in the future. A molecular diagnostic test for the Ebola Zaire virus has received Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA, Silver Springs, MD, USA) and may be used to detect Ebola Zaire virus in patients with signs and symptoms of Ebola virus disease.
The Idylla Ebola Virus Triage Test (Biocartis, Mechelen, Belgium) is a real-time reverse transcription polymerase chain reaction (rRT–PCR) test intended for the qualitative detection of ribonucleic acid (RNA) from the Ebola Zaire virus that was detected in the West Africa outbreak in 2014, in Ethylenediaminetetraacetic acid (EDTA) venous whole blood from individuals with signs and symptoms of Ebola virus infection in conjunction with epidemiological risk factors. The test, which delivers results within 100 minutes on a single cartridge, runs on the Biocartis Idylla platform, a fully automated, sample-to-result, real-time RT-PCR system, which allows for rapid deployment in both developed and emerging market countries.
The Idylla Ebola Virus Triage Test sample manipulation is reduced to a single step, i.e. entering the blood sample into the Idylla cartridge, after which the cartridge becomes a hermetically closed container. This reduces the risk of exposure to the Ebola virus for healthcare workers. Furthermore, the Idylla Ebola Virus Triage Test requires only minimal training of healthcare professionals and can be transported and stored at ambient temperature conditions, which enables rapid global deployment during outbreaks. Due to the difficulty in obtaining clinical specimens positive for Ebola, the Idylla Ebola Virus Triage Test was evaluated with limited numbers of contrived specimens spiked with live Ebola Zaire virus RNA.
Rudi Pauwels, PhD, Founder and Chief Executive Officer at Biocartis, said, “The 2014 Ebola and more recently the Zika outbreak, demonstrates that in today’s global world we need rapid, highly accurate and easily deployable diagnostic systems. The Idylla Ebola Virus Triage Test is the first infectious disease outbreak test authorized by the FDA on our Idylla platform, which is perfectly suited for outbreak control through early and fast testing. The test allows healthcare professionals in the field to rapidly diagnose infection, implement control measures and as such, open doors to faster and better treatment decisions.”
Related Links:
US Food and Drug Administration
Biocartis
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Portable POCT Blood Gas Analyzer
BD100
Immunofluorescence Analyzer
IFA System
Latest Microbiology News
- Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
- FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
- One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
- FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
- New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
- Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
- Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
- Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk
- FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing
- Expanded Newborn Screening Program Increases Detection of Congenital Cytomegalovirus
- Genetic Studies Uncover Mechanisms Driving Drug Resistance in Superbugs
- Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
- Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
- Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
- Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
- Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Channels
Clinical Chemistry
view channel
UK Project Advances Blood-Based Dementia Testing Toward Routine Clinical Care
Dementia is the leading cause of death in the UK, accounting for almost one in eight deaths, with more than 72,000 people dying from dementia, including Alzheimer’s disease, in 2025. Despite this burden,... Read more
Noninvasive AI-Enabled Raman Probe Distinguishes Skin Cancers from Normal Tissue
Skin cancer is the most common cancer in the United States and among the most common worldwide. Nearly 1.5 million new cases were diagnosed globally in 2024, including nearly 340,000 melanomas.... Read more
Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders
Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more
Molecular Diagnostics
view channel
Facilitated Cascade Program Increases Genetic Testing in Hereditary Cancer Families
Hereditary cancer risk can extend beyond an individual patient to parents, siblings, and children. Although BRCA1 and BRCA2 mutations are linked to elevated risks of breast, ovarian, prostate, and other... Read more
Urine-Based RNA Improves Bladder Cancer Detection and Monitoring
Bladder cancer affects about 85,000 people in the United States each year and is prone to recurrence. Diagnosis and surveillance commonly rely on cystoscopy, an endoscopic examination that can miss up... Read more
Hematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Routine Newborn Blood Spots Can Measure GBS Antibody Levels
Group B Streptococcus (GBS) can cause serious infections in newborns. Protecting infants remains challenging because immune protection may depend on antibodies transferred from mother to baby before birth.... Read more
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
Pathology
view channel
Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
Glioma brain tumors are highly infiltrative and can extend into nearby healthy brain tissue, making tumor margins difficult to define during surgery. Residual tumor cells may contribute to recurrence and... Read more
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more
Technology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read more
Industry
view channel
Collaboration Advances Automated Benchtop Platform for Routine Blood Testing
Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Expanded Partnership Supports AI Biomarker Validation and Clinical Trial Deployment
CellCarta (Montreal, Canada) and Imagene AI (Miami, FL, USA) have expanded their collaboration to provide biopharma companies with a coordinated pathway for biomarker strategy, assay development, validation,... Read more
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more